Get the Stockscreener App
2.03
1.00%
0.02
Sellas Life Sciences Group Inc stock is traded at $2.03, with a volume of 5.60M.
It is up +1.00% in the last 24 hours and up +36.24% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$2.01
Open:
$2.04
24h Volume:
5.60M
Relative Volume:
1.41
Market Cap:
$289.16M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-1.4926
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
+16.67%
1M Performance:
+36.24%
6M Performance:
+23.03%
1Y Performance:
+135.88%
1-Day Range:
$1.99
$2.12
1-Week Range:
$1.75
$2.12
52-Week Range:
$0.772
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
2.03 | 286.31M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next - Yahoo Finance
Sellas Life Sciences draws retail buzz on SLS009 trial momentum – stock soars in pre-market - MSN
SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market - Stocktwits
SELLAS Life Sciences: Clinical Trials Ignite Stock Interest - timothysykes.com
Sellas Life Sciences rises after reporting encouraging AML clinical results - MSN
Sellas Life Sciences stock jumps after promising AML treatment data By Investing.com - Investing.com Nigeria
Sellas Life Sciences stock jumps after promising AML treatment data - Investing.com
SELLAS Rises On Positive Phase 2 Data Of SLS009 In Relapsed/Refractory AML-MR - Nasdaq
Sellas Life Says Phase 2 Study of Cancer Combination Treatment Shows 'Clinically Meaningful' Activity; Shares Up Pre-Bell - marketscreener.com
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - The Manila Times
SELLAS Life Sciences (NASDAQ: SLS) reports 58% response, 8.9-month OS in AML study - Stock Titan
Trend Recap: Is SELLAS Life Sciences Group Inc RXK3 stock cheap by valuation metricsJuly 2025 Snapshot & Capital Efficiency Focused Ideas - moha.gov.vn
Should You Track Refex Industries Limited as a LongTerm Growth Play - earlytimes.in
Sellas Life Sciences Progress Sparks Optimism in Market - StocksToTrade
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
SELLAS Life Sciences Gains Momentum with Impressive Phase 2 Data and Financial Strength - timothysykes.com
How institutional buying supports SELLAS Life Sciences Group Inc. stockShare Buyback & High Accuracy Trade Alerts - Newser
How SELLAS Life Sciences Group Inc. (RXK3) stock compares with top peersQuarterly Profit Review & Stock Portfolio Risk Control - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock cheap by valuation metrics2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock a contrarian opportunityBreakout Watch & Weekly Chart Analysis and Guides - Newser
SELLAS Life Sciences Group Inc RXK3 Stock Analysis and ForecastStock Split Announcements & Technical + Fundamental = Smarter Investing - earlytimes.in
[EFFECT] SELLAS Life Sciences Group, Inc. SEC Filing - Stock Titan
SELLAS Advances AML Pipeline With GPS And SLS009 - RTTNews
Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock - MarketBeat
Katherine Kalin Increases Stake in SELLAS Life Sciences Group Inc - GuruFocus
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares By Investing.com - Investing.com Nigeria
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares - Investing.com
[Form 4] SELLAS Life Sciences Group, Inc. Insider Trading Activity - Stock Titan
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsWeekly Gains Report & Precise Swing Trade Alerts - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivals2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of rebound - newser.com
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - MarketBeat
How risky is SELLAS Life Sciences Group Inc. stock nowPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdown2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
SELLAS Life Sciences Group Inc. stock prediction for this weekWeekly Investment Recap & Weekly Breakout Stock Alerts - newser.com
Why millennials buy SELLAS Life Sciences Group Inc. (RXK3) stock2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastWeekly Trade Analysis & Verified Trade Idea Suggestions - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulationWeekly Trend Report & Entry and Exit Point Strategies - newser.com
Is SELLAS Life Sciences Group Inc. reversing from oversold territory2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):